| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunoassay | 15 | 2025 | 100 | 3.090 |
Why?
|
| Pharmacogenetics | 14 | 2025 | 456 | 2.090 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 5 | 2025 | 105 | 1.680 |
Why?
|
| Pre-Eclampsia | 6 | 2025 | 268 | 1.660 |
Why?
|
| Placenta Growth Factor | 5 | 2025 | 81 | 1.610 |
Why?
|
| Clinical Chemistry Tests | 4 | 2019 | 11 | 1.590 |
Why?
|
| Pharmacogenomic Testing | 6 | 2025 | 107 | 1.570 |
Why?
|
| Antibodies, Viral | 4 | 2022 | 348 | 1.470 |
Why?
|
| Hemolysis | 4 | 2023 | 63 | 1.210 |
Why?
|
| Tacrolimus | 2 | 2024 | 373 | 1.130 |
Why?
|
| Tandem Mass Spectrometry | 4 | 2024 | 110 | 1.120 |
Why?
|
| Precision Medicine | 6 | 2025 | 454 | 1.080 |
Why?
|
| Cytochrome P-450 CYP2C19 | 3 | 2025 | 9 | 1.040 |
Why?
|
| Immunoglobulin M | 4 | 2021 | 165 | 1.030 |
Why?
|
| Interleukin-6 | 2 | 2025 | 281 | 0.820 |
Why?
|
| Biomarkers | 11 | 2025 | 1930 | 0.820 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2025 | 180 | 0.810 |
Why?
|
| Automation, Laboratory | 2 | 2020 | 12 | 0.810 |
Why?
|
| Peptide Fragments | 6 | 2011 | 477 | 0.800 |
Why?
|
| Humans | 84 | 2025 | 96105 | 0.790 |
Why?
|
| Vanadates | 1 | 2023 | 32 | 0.770 |
Why?
|
| Biotin | 1 | 2023 | 46 | 0.770 |
Why?
|
| Natriuretic Peptide, Brain | 5 | 2011 | 60 | 0.740 |
Why?
|
| Drug Monitoring | 2 | 2024 | 120 | 0.730 |
Why?
|
| Thyroid Function Tests | 1 | 2022 | 124 | 0.720 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2022 | 59 | 0.710 |
Why?
|
| Prostate-Specific Antigen | 1 | 2024 | 346 | 0.700 |
Why?
|
| Communicable Diseases, Imported | 1 | 2021 | 1 | 0.690 |
Why?
|
| Reproducibility of Results | 9 | 2025 | 2880 | 0.660 |
Why?
|
| Serologic Tests | 1 | 2020 | 43 | 0.660 |
Why?
|
| Blood Specimen Collection | 2 | 2012 | 28 | 0.660 |
Why?
|
| Betacoronavirus | 2 | 2020 | 284 | 0.650 |
Why?
|
| Hyperkalemia | 2 | 2012 | 18 | 0.650 |
Why?
|
| Patient Safety | 1 | 2023 | 223 | 0.650 |
Why?
|
| Triiodothyronine | 1 | 2022 | 362 | 0.630 |
Why?
|
| Endothelial Growth Factors | 10 | 1996 | 55 | 0.600 |
Why?
|
| Lymphokines | 10 | 1996 | 75 | 0.600 |
Why?
|
| Hyperparathyroidism, Primary | 1 | 2019 | 45 | 0.570 |
Why?
|
| Parathyroidectomy | 1 | 2019 | 79 | 0.570 |
Why?
|
| Vitamin B 12 | 1 | 2018 | 25 | 0.560 |
Why?
|
| Smith-Lemli-Opitz Syndrome | 1 | 2018 | 2 | 0.560 |
Why?
|
| Parathyroid Hormone | 1 | 2019 | 228 | 0.540 |
Why?
|
| Adalimumab | 1 | 2018 | 92 | 0.530 |
Why?
|
| Testosterone | 2 | 2017 | 277 | 0.530 |
Why?
|
| Cholesterol | 2 | 2024 | 369 | 0.520 |
Why?
|
| Hypogonadism | 1 | 2017 | 44 | 0.520 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 3 | 2011 | 44 | 0.500 |
Why?
|
| Chromatography, Liquid | 3 | 2024 | 104 | 0.490 |
Why?
|
| Developmental Disabilities | 1 | 2018 | 208 | 0.480 |
Why?
|
| Cytochrome P-450 CYP2D6 | 5 | 2022 | 52 | 0.480 |
Why?
|
| Proteomics | 1 | 2018 | 268 | 0.480 |
Why?
|
| Immunoglobulin G | 4 | 2021 | 481 | 0.480 |
Why?
|
| Stroke | 1 | 2025 | 1087 | 0.480 |
Why?
|
| Sensitivity and Specificity | 6 | 2022 | 2039 | 0.470 |
Why?
|
| Chorionic Gonadotropin | 2 | 2014 | 72 | 0.470 |
Why?
|
| Fibromyalgia | 1 | 2015 | 16 | 0.460 |
Why?
|
| Immunosuppressive Agents | 2 | 2024 | 995 | 0.440 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2014 | 45 | 0.420 |
Why?
|
| Pregnancy | 9 | 2025 | 3240 | 0.420 |
Why?
|
| Analgesics | 1 | 2015 | 132 | 0.420 |
Why?
|
| Genotype | 7 | 2022 | 1881 | 0.410 |
Why?
|
| Myocardial Ischemia | 2 | 2005 | 167 | 0.410 |
Why?
|
| Carcinoma, Papillary | 1 | 2014 | 161 | 0.390 |
Why?
|
| Pharmacogenomic Variants | 2 | 2025 | 44 | 0.380 |
Why?
|
| Prostatic Neoplasms | 1 | 2024 | 1798 | 0.380 |
Why?
|
| Reagent Kits, Diagnostic | 4 | 2020 | 39 | 0.380 |
Why?
|
| Chronic Pain | 1 | 2015 | 186 | 0.370 |
Why?
|
| Troponin I | 3 | 2003 | 27 | 0.350 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2025 | 123 | 0.350 |
Why?
|
| Nerve Tissue Proteins | 2 | 2004 | 515 | 0.340 |
Why?
|
| Diagnostic Errors | 1 | 2012 | 159 | 0.340 |
Why?
|
| Potassium | 1 | 2012 | 271 | 0.340 |
Why?
|
| Artifacts | 1 | 2012 | 252 | 0.330 |
Why?
|
| Genotyping Techniques | 1 | 2011 | 71 | 0.330 |
Why?
|
| Female | 27 | 2025 | 50028 | 0.330 |
Why?
|
| Legislation, Medical | 1 | 2010 | 9 | 0.330 |
Why?
|
| Warfarin | 2 | 2019 | 107 | 0.320 |
Why?
|
| Thyroid Neoplasms | 1 | 2014 | 443 | 0.310 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2021 | 2494 | 0.310 |
Why?
|
| Antibodies, Heterophile | 2 | 2000 | 20 | 0.310 |
Why?
|
| Anticoagulants | 3 | 2019 | 463 | 0.300 |
Why?
|
| Oxycodone | 2 | 2022 | 35 | 0.280 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2014 | 1471 | 0.270 |
Why?
|
| False Positive Reactions | 4 | 2020 | 222 | 0.270 |
Why?
|
| Alleles | 3 | 2025 | 1157 | 0.260 |
Why?
|
| Adult | 21 | 2025 | 28721 | 0.250 |
Why?
|
| Limit of Detection | 2 | 2018 | 21 | 0.240 |
Why?
|
| Inpatients | 3 | 2025 | 347 | 0.240 |
Why?
|
| Drug Prescriptions | 2 | 2025 | 151 | 0.240 |
Why?
|
| Bilirubin | 2 | 2023 | 134 | 0.240 |
Why?
|
| Rifampin | 1 | 2006 | 23 | 0.240 |
Why?
|
| Protein Precursors | 2 | 2011 | 138 | 0.230 |
Why?
|
| Exercise | 2 | 2005 | 354 | 0.220 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2022 | 209 | 0.220 |
Why?
|
| Paper | 1 | 2024 | 12 | 0.220 |
Why?
|
| Transistors, Electronic | 1 | 2024 | 6 | 0.220 |
Why?
|
| Male | 19 | 2025 | 45863 | 0.210 |
Why?
|
| Aspirin | 1 | 2025 | 169 | 0.210 |
Why?
|
| Biosensing Techniques | 1 | 2024 | 81 | 0.200 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 1 | 2023 | 24 | 0.200 |
Why?
|
| Gene Frequency | 1 | 2025 | 703 | 0.200 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2023 | 72 | 0.200 |
Why?
|
| Infant, Newborn | 5 | 2022 | 2614 | 0.190 |
Why?
|
| Predictive Value of Tests | 4 | 2018 | 1805 | 0.190 |
Why?
|
| Cardiolipins | 1 | 2002 | 17 | 0.190 |
Why?
|
| Erythrocyte Transfusion | 2 | 2013 | 75 | 0.190 |
Why?
|
| Patient Care Team | 1 | 2025 | 307 | 0.190 |
Why?
|
| Risk Assessment | 3 | 2025 | 2480 | 0.190 |
Why?
|
| Bias | 1 | 2023 | 139 | 0.180 |
Why?
|
| Middle Aged | 16 | 2025 | 28368 | 0.180 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2005 | 340 | 0.180 |
Why?
|
| Neonatal Sepsis | 1 | 2022 | 6 | 0.180 |
Why?
|
| Tramadol | 1 | 2022 | 14 | 0.180 |
Why?
|
| Chorioamnionitis | 1 | 2022 | 23 | 0.180 |
Why?
|
| Prospective Studies | 8 | 2025 | 4671 | 0.180 |
Why?
|
| Erythrocytes | 2 | 2013 | 254 | 0.180 |
Why?
|
| Travel Medicine | 1 | 2021 | 1 | 0.170 |
Why?
|
| Autoantibodies | 1 | 2002 | 281 | 0.170 |
Why?
|
| Perioperative Care | 2 | 2022 | 188 | 0.170 |
Why?
|
| Pain Management | 2 | 2021 | 179 | 0.170 |
Why?
|
| Liver | 1 | 2006 | 1238 | 0.170 |
Why?
|
| Cross Reactions | 1 | 2021 | 115 | 0.170 |
Why?
|
| Bacteremia | 1 | 2022 | 108 | 0.170 |
Why?
|
| Fetal Growth Retardation | 1 | 2021 | 72 | 0.170 |
Why?
|
| Jaundice | 1 | 2020 | 14 | 0.160 |
Why?
|
| Blood Proteins | 1 | 2001 | 151 | 0.160 |
Why?
|
| Equipment Design | 2 | 2021 | 427 | 0.160 |
Why?
|
| Thyroid Gland | 1 | 2022 | 281 | 0.160 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 79 | 0.160 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2020 | 25 | 0.160 |
Why?
|
| Hyperglycemia | 2 | 2001 | 181 | 0.160 |
Why?
|
| Hepatitis B Antibodies | 1 | 2020 | 16 | 0.160 |
Why?
|
| Indicators and Reagents | 1 | 2000 | 71 | 0.160 |
Why?
|
| Blood Chemical Analysis | 1 | 2000 | 41 | 0.160 |
Why?
|
| Hyperlipidemias | 1 | 2020 | 91 | 0.160 |
Why?
|
| Platelet Function Tests | 1 | 2019 | 11 | 0.160 |
Why?
|
| Glycoproteins | 1 | 2001 | 233 | 0.160 |
Why?
|
| Genomics | 2 | 2019 | 857 | 0.160 |
Why?
|
| Mixed Function Oxygenases | 2 | 2010 | 69 | 0.150 |
Why?
|
| Vascular Endothelial Growth Factors | 10 | 1996 | 55 | 0.150 |
Why?
|
| Early Detection of Cancer | 1 | 2024 | 484 | 0.150 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2019 | 30 | 0.150 |
Why?
|
| Case-Control Studies | 5 | 2022 | 1957 | 0.150 |
Why?
|
| Peripartum Period | 1 | 2019 | 29 | 0.150 |
Why?
|
| Medication Adherence | 1 | 2020 | 122 | 0.150 |
Why?
|
| Intraoperative Period | 1 | 2019 | 98 | 0.150 |
Why?
|
| Acute Kidney Injury | 1 | 2023 | 340 | 0.150 |
Why?
|
| High-Throughput Screening Assays | 1 | 2019 | 62 | 0.150 |
Why?
|
| Serotonin | 1 | 2019 | 219 | 0.140 |
Why?
|
| Blood Pressure | 3 | 2019 | 926 | 0.140 |
Why?
|
| Decision Support Techniques | 1 | 2020 | 186 | 0.140 |
Why?
|
| Dehydrocholesterols | 1 | 2018 | 2 | 0.140 |
Why?
|
| Biological Availability | 1 | 2018 | 89 | 0.140 |
Why?
|
| Chromatography, High Pressure Liquid | 3 | 2019 | 311 | 0.140 |
Why?
|
| Vascular Endothelial Growth Factor A | 10 | 1996 | 403 | 0.130 |
Why?
|
| Sepsis | 1 | 2022 | 391 | 0.130 |
Why?
|
| Anesthesiology | 1 | 2019 | 168 | 0.130 |
Why?
|
| Vitamin D | 1 | 2019 | 273 | 0.130 |
Why?
|
| Prognosis | 4 | 2019 | 4028 | 0.130 |
Why?
|
| Administration, Cutaneous | 2 | 2015 | 61 | 0.130 |
Why?
|
| Myocardium | 1 | 2000 | 592 | 0.130 |
Why?
|
| Analgesics, Opioid | 1 | 2021 | 513 | 0.130 |
Why?
|
| Diabetic Retinopathy | 2 | 1994 | 82 | 0.120 |
Why?
|
| Retrospective Studies | 5 | 2023 | 10287 | 0.120 |
Why?
|
| Ovarian Hyperstimulation Syndrome | 1 | 1996 | 5 | 0.120 |
Why?
|
| Pilot Projects | 2 | 2018 | 938 | 0.120 |
Why?
|
| Fluoroimmunoassay | 2 | 1994 | 2 | 0.120 |
Why?
|
| Autoimmune Diseases | 1 | 2018 | 257 | 0.120 |
Why?
|
| Critical Care | 1 | 2019 | 447 | 0.120 |
Why?
|
| Child | 3 | 2023 | 7625 | 0.120 |
Why?
|
| Hypertension | 3 | 2018 | 774 | 0.120 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2001 | 595 | 0.120 |
Why?
|
| Myalgia | 1 | 2015 | 7 | 0.120 |
Why?
|
| Libido | 1 | 2015 | 9 | 0.120 |
Why?
|
| Health Promotion | 1 | 2017 | 176 | 0.110 |
Why?
|
| Gels | 1 | 2015 | 53 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 346 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 334 | 0.110 |
Why?
|
| Biomarkers, Tumor | 1 | 2024 | 1670 | 0.110 |
Why?
|
| Heart Failure | 1 | 2005 | 1422 | 0.110 |
Why?
|
| Blood Glucose | 3 | 2017 | 873 | 0.110 |
Why?
|
| Quality Control | 2 | 2012 | 125 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2018 | 713 | 0.110 |
Why?
|
| Vitreous Body | 1 | 1994 | 54 | 0.110 |
Why?
|
| Fatigue | 1 | 2015 | 185 | 0.110 |
Why?
|
| Calibration | 1 | 2014 | 108 | 0.100 |
Why?
|
| Mass Spectrometry | 2 | 2014 | 206 | 0.100 |
Why?
|
| Time Factors | 5 | 2012 | 5580 | 0.100 |
Why?
|
| Blood Preservation | 1 | 2013 | 11 | 0.100 |
Why?
|
| Hemoglobin, Sickle | 1 | 2013 | 17 | 0.100 |
Why?
|
| Hyperammonemia | 1 | 2013 | 14 | 0.100 |
Why?
|
| Vitamin K Epoxide Reductases | 2 | 2010 | 16 | 0.100 |
Why?
|
| Cytochrome P-450 CYP2C9 | 2 | 2010 | 20 | 0.100 |
Why?
|
| Diagnosis, Differential | 2 | 2014 | 1619 | 0.100 |
Why?
|
| Centrifugation | 1 | 2012 | 24 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2001 | 1230 | 0.090 |
Why?
|
| Phlebotomy | 1 | 2012 | 23 | 0.090 |
Why?
|
| Aged | 9 | 2025 | 20968 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 1021 | 0.090 |
Why?
|
| Chest Pain | 1 | 2011 | 48 | 0.090 |
Why?
|
| Ambulatory Care Facilities | 1 | 2012 | 118 | 0.090 |
Why?
|
| Acute Coronary Syndrome | 1 | 2011 | 34 | 0.090 |
Why?
|
| Smoking | 2 | 2006 | 653 | 0.080 |
Why?
|
| Anemia, Sickle Cell | 1 | 2013 | 150 | 0.080 |
Why?
|
| Drug Industry | 1 | 2011 | 59 | 0.080 |
Why?
|
| Insulin | 2 | 2006 | 1190 | 0.080 |
Why?
|
| Drug Therapy | 1 | 2010 | 70 | 0.080 |
Why?
|
| Cell Line | 2 | 2011 | 2537 | 0.080 |
Why?
|
| Genetic Markers | 1 | 2010 | 479 | 0.080 |
Why?
|
| Glucuronosyltransferase | 1 | 2010 | 186 | 0.080 |
Why?
|
| Pharmaceutical Preparations | 1 | 2010 | 97 | 0.070 |
Why?
|
| Pain | 2 | 2022 | 426 | 0.070 |
Why?
|
| Vancomycin | 1 | 1989 | 75 | 0.070 |
Why?
|
| Troponin T | 2 | 2011 | 44 | 0.070 |
Why?
|
| United States Food and Drug Administration | 1 | 2009 | 147 | 0.070 |
Why?
|
| Aged, 80 and over | 5 | 2025 | 7229 | 0.070 |
Why?
|
| Leukocyte Count | 1 | 2008 | 228 | 0.070 |
Why?
|
| Neoplasms | 2 | 2021 | 3248 | 0.070 |
Why?
|
| Young Adult | 4 | 2025 | 7025 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 897 | 0.070 |
Why?
|
| Surveys and Questionnaires | 1 | 2015 | 2860 | 0.060 |
Why?
|
| Emergency Service, Hospital | 1 | 2011 | 594 | 0.060 |
Why?
|
| Nanotechnology | 1 | 2007 | 73 | 0.060 |
Why?
|
| Sequence Deletion | 1 | 2007 | 212 | 0.060 |
Why?
|
| Gene Duplication | 1 | 2007 | 129 | 0.060 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2006 | 41 | 0.060 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2006 | 42 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 1179 | 0.060 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2006 | 78 | 0.060 |
Why?
|
| Narcotics | 1 | 2006 | 72 | 0.060 |
Why?
|
| Diabetes Mellitus | 2 | 2017 | 771 | 0.060 |
Why?
|
| Hydrocortisone | 2 | 2004 | 300 | 0.060 |
Why?
|
| Molecular Structure | 1 | 2006 | 310 | 0.060 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2021 | 647 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2005 | 183 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2007 | 701 | 0.060 |
Why?
|
| Algorithms | 1 | 2013 | 2015 | 0.050 |
Why?
|
| Cohort Studies | 3 | 2019 | 3110 | 0.050 |
Why?
|
| Radionuclide Imaging | 1 | 2004 | 217 | 0.050 |
Why?
|
| Human Growth Hormone | 1 | 2004 | 55 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2005 | 599 | 0.050 |
Why?
|
| Edetic Acid | 1 | 2003 | 42 | 0.050 |
Why?
|
| Exercise Test | 1 | 2004 | 178 | 0.050 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2023 | 23 | 0.050 |
Why?
|
| Ischemia | 1 | 2005 | 256 | 0.050 |
Why?
|
| Kinetics | 2 | 2024 | 1562 | 0.050 |
Why?
|
| Hypoglycemic Agents | 1 | 2006 | 376 | 0.050 |
Why?
|
| Aspartate Aminotransferases | 1 | 2023 | 75 | 0.050 |
Why?
|
| Adolescent | 3 | 2021 | 9895 | 0.050 |
Why?
|
| Pharmacists | 1 | 2022 | 36 | 0.050 |
Why?
|
| Nicotine | 1 | 2004 | 210 | 0.050 |
Why?
|
| Omeprazole | 1 | 2022 | 11 | 0.050 |
Why?
|
| Succinylcholine | 1 | 2022 | 14 | 0.050 |
Why?
|
| ROC Curve | 1 | 2004 | 797 | 0.050 |
Why?
|
| Temperature | 1 | 2003 | 426 | 0.050 |
Why?
|
| Hydralazine | 1 | 2022 | 21 | 0.050 |
Why?
|
| Methylprednisolone | 1 | 2002 | 68 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2015 | 9175 | 0.050 |
Why?
|
| United States | 2 | 2019 | 7768 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2002 | 380 | 0.040 |
Why?
|
| Dibenzothiazepines | 1 | 2001 | 4 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2025 | 413 | 0.040 |
Why?
|
| Inflammation Mediators | 1 | 2002 | 161 | 0.040 |
Why?
|
| Risperidone | 1 | 2001 | 24 | 0.040 |
Why?
|
| Risk Factors | 3 | 2022 | 5961 | 0.040 |
Why?
|
| Heart Diseases | 1 | 2003 | 314 | 0.040 |
Why?
|
| Long QT Syndrome | 1 | 2001 | 39 | 0.040 |
Why?
|
| Phenotype | 1 | 2007 | 2578 | 0.040 |
Why?
|
| Coronary Artery Bypass | 1 | 2002 | 252 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 2000 | 271 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2002 | 369 | 0.040 |
Why?
|
| Antipsychotic Agents | 1 | 2001 | 151 | 0.040 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2002 | 358 | 0.040 |
Why?
|
| Binding, Competitive | 1 | 2019 | 147 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2023 | 502 | 0.040 |
Why?
|
| Morbidity | 1 | 2019 | 160 | 0.040 |
Why?
|
| Point-of-Care Systems | 1 | 2019 | 155 | 0.040 |
Why?
|
| Aortic Aneurysm | 1 | 1998 | 82 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 540 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 296 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 1176 | 0.030 |
Why?
|
| Pain, Postoperative | 1 | 2019 | 277 | 0.030 |
Why?
|
| Pregnancy Outcome | 1 | 2018 | 273 | 0.030 |
Why?
|
| Follicular Fluid | 1 | 1996 | 10 | 0.030 |
Why?
|
| Ovulation Induction | 1 | 1996 | 32 | 0.030 |
Why?
|
| Ascitic Fluid | 1 | 1996 | 38 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2022 | 847 | 0.030 |
Why?
|
| Osmolar Concentration | 1 | 1996 | 180 | 0.030 |
Why?
|
| Semen | 1 | 1995 | 17 | 0.030 |
Why?
|
| Mitogens | 1 | 1995 | 61 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 3927 | 0.030 |
Why?
|
| Seminal Vesicles | 1 | 1995 | 39 | 0.030 |
Why?
|
| Cardiopulmonary Bypass | 2 | 2002 | 162 | 0.030 |
Why?
|
| Protein Binding | 1 | 2019 | 1560 | 0.030 |
Why?
|
| Skin Diseases, Vesiculobullous | 1 | 1995 | 18 | 0.030 |
Why?
|
| Fetal Blood | 1 | 1995 | 96 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 935 | 0.030 |
Why?
|
| Birth Weight | 1 | 1995 | 152 | 0.030 |
Why?
|
| DNA, Complementary | 1 | 1996 | 394 | 0.030 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 1995 | 111 | 0.030 |
Why?
|
| Survival Rate | 1 | 2019 | 1985 | 0.030 |
Why?
|
| Receptors, Growth Factor | 1 | 1994 | 52 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 682 | 0.030 |
Why?
|
| Infant | 1 | 2021 | 3363 | 0.030 |
Why?
|
| Cross-Over Studies | 2 | 2006 | 397 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 880 | 0.030 |
Why?
|
| Chicago | 1 | 2018 | 1506 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 1996 | 354 | 0.030 |
Why?
|
| Leukocyte Reduction Procedures | 1 | 2013 | 3 | 0.030 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 1994 | 159 | 0.030 |
Why?
|
| Hematocrit | 1 | 2013 | 69 | 0.030 |
Why?
|
| Ammonia | 1 | 2013 | 45 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 1995 | 437 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 1979 | 0.020 |
Why?
|
| Automation | 1 | 2013 | 115 | 0.020 |
Why?
|
| Fibrin | 1 | 1992 | 87 | 0.020 |
Why?
|
| Microcirculation | 1 | 1992 | 104 | 0.020 |
Why?
|
| Europium | 1 | 1992 | 1 | 0.020 |
Why?
|
| Guinea Pigs | 1 | 1992 | 172 | 0.020 |
Why?
|
| Body Weight | 1 | 2013 | 460 | 0.020 |
Why?
|
| Prostate | 1 | 1995 | 423 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 1992 | 128 | 0.020 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2011 | 25 | 0.020 |
Why?
|
| Animals | 3 | 2005 | 28891 | 0.020 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2011 | 68 | 0.020 |
Why?
|
| Psoriasis | 1 | 1994 | 254 | 0.020 |
Why?
|
| Greece | 1 | 2011 | 20 | 0.020 |
Why?
|
| Melanoma | 1 | 1996 | 497 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 1994 | 3040 | 0.020 |
Why?
|
| Albumins | 1 | 2011 | 135 | 0.020 |
Why?
|
| Pathology, Molecular | 1 | 2010 | 34 | 0.020 |
Why?
|
| Obesity | 1 | 2017 | 1030 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 1995 | 1876 | 0.020 |
Why?
|
| Autoanalysis | 1 | 1989 | 6 | 0.020 |
Why?
|
| Atrial Natriuretic Factor | 1 | 1989 | 39 | 0.020 |
Why?
|
| Heart Arrest, Induced | 1 | 1989 | 30 | 0.020 |
Why?
|
| Creatine | 1 | 1989 | 28 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 1989 | 298 | 0.020 |
Why?
|
| Double-Blind Method | 2 | 2004 | 1791 | 0.020 |
Why?
|
| Hypothermia, Induced | 1 | 1989 | 91 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 1992 | 2090 | 0.020 |
Why?
|
| Digoxin | 1 | 1987 | 21 | 0.020 |
Why?
|
| Absorption | 1 | 2006 | 26 | 0.020 |
Why?
|
| Glucose Clamp Technique | 1 | 2006 | 43 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2006 | 134 | 0.020 |
Why?
|
| Administration, Inhalation | 1 | 2006 | 203 | 0.010 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2006 | 62 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2006 | 340 | 0.010 |
Why?
|
| Genome, Human | 1 | 2010 | 824 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1989 | 1973 | 0.010 |
Why?
|
| Mass Screening | 1 | 1990 | 710 | 0.010 |
Why?
|
| Transforming Growth Factor alpha | 2 | 1995 | 50 | 0.010 |
Why?
|
| DNA | 1 | 2010 | 1333 | 0.010 |
Why?
|
| Glucose Tolerance Test | 1 | 2004 | 235 | 0.010 |
Why?
|
| Insulin Resistance | 1 | 2006 | 380 | 0.010 |
Why?
|
| Reference Values | 1 | 2003 | 674 | 0.010 |
Why?
|
| Postoperative Nausea and Vomiting | 1 | 2002 | 19 | 0.010 |
Why?
|
| Etomidate | 1 | 2002 | 11 | 0.010 |
Why?
|
| Quetiapine Fumarate | 1 | 2001 | 4 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2002 | 166 | 0.010 |
Why?
|
| Respiratory Mechanics | 1 | 2002 | 114 | 0.010 |
Why?
|
| Smoking Cessation | 1 | 2004 | 272 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 2003 | 429 | 0.010 |
Why?
|
| Cells, Cultured | 2 | 1995 | 2939 | 0.010 |
Why?
|
| RNA, Messenger | 2 | 1995 | 2090 | 0.010 |
Why?
|
| Hemodynamics | 1 | 2002 | 775 | 0.010 |
Why?
|
| Gene Expression Regulation | 2 | 1995 | 2061 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 1996 | 67 | 0.010 |
Why?
|
| Erythema Multiforme | 1 | 1995 | 4 | 0.010 |
Why?
|
| Dermatitis Herpetiformis | 1 | 1995 | 9 | 0.010 |
Why?
|
| Pemphigoid, Bullous | 1 | 1995 | 12 | 0.010 |
Why?
|
| Mice, SCID | 1 | 1996 | 279 | 0.010 |
Why?
|
| Epidermal Growth Factor | 1 | 1995 | 116 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 1995 | 103 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 1995 | 312 | 0.010 |
Why?
|
| Receptors, Immunologic | 1 | 1995 | 145 | 0.010 |
Why?
|
| Keratinocytes | 1 | 1995 | 146 | 0.010 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 1994 | 62 | 0.010 |
Why?
|
| Cell Division | 1 | 1996 | 705 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1996 | 1049 | 0.010 |
Why?
|
| Transfection | 1 | 1996 | 908 | 0.010 |
Why?
|
| Mice, Nude | 1 | 1996 | 830 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1995 | 1034 | 0.010 |
Why?
|
| Fibrinogen | 1 | 1992 | 52 | 0.010 |
Why?
|
| Binding Sites | 1 | 1995 | 1167 | 0.010 |
Why?
|
| Blood Coagulation | 1 | 1992 | 90 | 0.010 |
Why?
|
| Capillary Permeability | 1 | 1992 | 132 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 1996 | 1094 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 1995 | 1828 | 0.010 |
Why?
|
| Gene Expression | 1 | 1995 | 1320 | 0.010 |
Why?
|
| Base Sequence | 1 | 1994 | 2344 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2002 | 2591 | 0.010 |
Why?
|
| Singapore | 1 | 1990 | 15 | 0.010 |
Why?
|
| Diabetic Nephropathies | 1 | 1990 | 90 | 0.000 |
Why?
|
| Myocardial Revascularization | 1 | 1989 | 32 | 0.000 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 1989 | 123 | 0.000 |
Why?
|
| Heart Valve Prosthesis | 1 | 1989 | 106 | 0.000 |
Why?
|
| Heparin | 1 | 1989 | 186 | 0.000 |
Why?
|
| Ultrafiltration | 1 | 1987 | 13 | 0.000 |
Why?
|
| Hemofiltration | 1 | 1987 | 11 | 0.000 |
Why?
|
| Radioimmunoassay | 1 | 1987 | 150 | 0.000 |
Why?
|
| Solvents | 1 | 1987 | 91 | 0.000 |
Why?
|
| Mitral Valve | 1 | 1989 | 279 | 0.000 |
Why?
|
| Heart Rate | 1 | 1989 | 518 | 0.000 |
Why?
|
| Sex Factors | 1 | 1990 | 1133 | 0.000 |
Why?
|
| Prevalence | 1 | 1990 | 1349 | 0.000 |
Why?
|
| Mice | 1 | 1996 | 12537 | 0.000 |
Why?
|